Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria- a systematic review for the EAACI Biologicals Guidelines


1 Transylvania University of Brasov
2 Biomedical Research Institute Sant Pau
3 Hospital Sant Pau
4 Biomedical Research Institute
5 IMIM
6 University of Zurich
7 University of Zürich
8 Technical University of Munich
9 Univ CEU San Pablo
10 University of Cagliari Faculty of Medicine
11 The Hospital for Sick Children
12 TUM
13 Hospital del Mar. Institut Mar d’Investigacions Mediques
14 Universitair Ziekenhuis Brussel
15 Rockefeller University
16 Charité Universitätsmedizin Berlin
17 University of Oxford
18 Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine
19 University College Cork National University of Ireland
20 University of Edinburgh, Edinburgh
21 Hannover Medical School
22 Complutense University of Madrid
23 Wroclaw Medical University

July 8, 2020

Abstract

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). Pubmed,
EMBASE and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg: does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS7) (mean difference (MD) -5; 95% CI -7.75 to -2.25) and the itch severity score (ISS7) (MD -2.15; 95% CI -3.2 to -1.1); does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95% CI -3.22 to -0.81); decreases (moderate certainty) rescue medication use (MD -1.68; 95% CI -2.95 to -0.4). Omalizumab 300 mg: results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95% CI -12.87 to -9.24), the ISS7 (MD -4.45; 95% CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5); decreases (moderate certainty) rescue medication use (MD -2.04; 95% CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95% CI 0.20 to 2.91).

Hosted file

Hosted file